Browsing by Author Forbes, John F.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 19 of 19
Issue DateTitleAuthor(s)Citation
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2016Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to VCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Forbes, John F.; Gelber, Richard; Gianni, Lorenzo; Goldhirsch, Aron; Karlsson, Per; Price, Karen; Sun, Zhuoxin; Thurlimann, B.; School of Public Health: Public HealthAnnual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V, Journal of Clinical Oncology, vol.34, 9, 2016,pp 927-935
2015Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsCoates, Alan; Aihara, T; Bliss, J; Boccardo, F; Bradley, R; Coombes, R; Cuzick, J; Dowsett, Mitch (Prof); Dubsky, P; et al, Various; Forbes, John F.; Gnant, Michael; Ingle, J.; Kaufmann, Michael; Kilburn, L; School of Public Health: Public HealthAromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials, The Lancet, vol.386, 10001, 2015,pp 1341-1352
2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-upCoates, Alan; Ejlertsen, Bent; Forbes, John F.; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Neven, Patrick; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, B.; Wardley, Andrew; School of Public Health: Public HealthAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncology, vol.12, 12, 2011,pp 1101-1108
2007Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; et, al; Forbes, John F.; Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Rabaglio, Manuela; Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthCardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.25,(36),2007,pp 5715-5722
2005A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.Coates, Alan; Castiglione-Gertsch, Monica; et, al; Forbes, John F.; Gelber, Richard D. (Prof); Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Rabaglio, Manuela; Thurlimann, Beat; School of Public Health: Public HealthA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer., New England Journal of Medicine, vol.353,(26),2005,pp 2747-2757
2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; et, al; Forbes, John F.; Gelber, Richard D. (Prof); Keshaviah, Aparna; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Thurlimann, Beat; School of Public Health: Public HealthFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.25,(5),2007,pp 486-492
2014Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trialBell, Melanie Lynn; Bonner, Carissa; Boyle, Frances; Butow, Phyllis; Juraskova, Ilona; Smith, Allan; Cuzick, J.; Forbes, John F.; Reaby, L; Seccombe, M; Psychology; School of Public Health: Medicine; Northern Clinical School: Medicine; Psychology; Psychology; PsychologyImproving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial, British Journal of Cancer, vol.111, 1, 2014,pp 1-17
2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Collins, John; Crivellari, Diana; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Holmberg, Stig B.; Price, Karen; Thurlimann, Beat; School of Public Health: Public HealthIs chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93., Breast Cancer Research and Treatment, vol.113,(N/A),2009,pp 137-144
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.Coates, Alan; et al, various; Forbes, John F.; Giobbie-Hurder, Anita; Goldhirsch, Aron; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Smith, Ian (Prof); Thurlimann, Beat; School of Public Health: Public HealthLetrozole therapy alone or in sequence with tamoxifen in women with breast cancer., New England Journal of Medicine, vol.361, 8,pp 766-776
2012Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 TrialCoates, Alan; Bonnefoi, Herve; Ejlertsen, Bent; et al, Various; Ewertz, Marianne; Forbes, John F.; Gray, Kathryn P; Paridaens, R.J.; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Thurlimann, Beat; School of Public Health: Public HealthObesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial, Journal of Clinical Oncology, vol.30, 32, 2012,pp 3967-3975
2016Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trialCoates, Alan; Davies, Lucy; Gebski, Val; Bayliss, E; Boyle, F M; Della-Fiorentina, S; et al, Various; Forbes, John F.; Gill, P Grantley; Kannourakis, G; Kling, N; Saunders, Christobel; Zdenkowski, Nicholas; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreObservation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial, Annals of Oncology, vol.27, 5, 2016,pp 806-812
2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialCoates, Alan; Debled, M.; et, al; Forbes, John F.; Keshaviah, Aparna; Lang, I.; Mauriac, L; Monnier, Arnaud; Mouridsen, Henning; Paridaens, Robert; Thurlimann, Beat; School of Public Health: Public HealthPredictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Annals of Oncology 2005, vol.18,(5),2007,pp 859-867
2006Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.Coates, Alan; Bernhard, Jurg; Campbell, Ian; Crivellari, Diana; Dent, David; et, al; Forbes, John F.; Holmberg, Stig B.; Rey, Piercarlo; Rudenstam, Carl-Magnus; Zahrieh, David; School of Public Health: Public HealthRandomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(3),2006,pp 337-344
2006A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatmentCoates, Alan; Gebski, Val; Simes, Robert John; Sourjina, Tatiana; Stockler, Martin; Ackland, Stephen P.; Byrne, Michael J.; Finch, K; Fitzharris, B; Forbes, John F.; Frances, P; Harvey, V; Kato-Fong, A; Lindsay, Dianne; Paksec, Lisa; van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment, Breast Cancer Research and Treatment, vol.100, Supplement 1,pp S278-S278
2014Symptoms of endocrine treatment and outcome in the BIG 1-98 studyCoates, Alan; Bonnefoi, Herve; Cole, B F; Ejlertsen, Bent; et al, Various; Forbes, John F.; Giobbie-Hurder, Anita; Huober, J; Lang, Istvan; Neven, Patrick; Rabaglio, Manuela; Wu, Junru; School of Public Health: Public HealthSymptoms of endocrine treatment and outcome in the BIG 1-98 study, Breast Cancer Research and Treatment, vol.143, 1, 2014,pp 159-169
2005Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumorCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Collins, John; Crivellari, Diana; Erzen, Darja; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Holmberg, S.; Li, S.; Lindtner, Jurii; Murray, E.; Pagani, O.; Price, K. N.; Rudenstam, Carl-Magnus; Simoncini, Edda; Thurlimann, Beat; Veronesi, A.; School of Public Health: Public HealthTiming of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor, Annals of Oncology 2005, vol.16,(5),2005,pp 716-725
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7